

FIGURE 1A

RMA vs RMA S +/- IFN, VSV




FIGURE 1B

CMT64 +/- IFN, VSV




FIGURE 2






FIGURE 3

CMT 64 +/- VSV; Superinfection with Vac, or Vacb2




60370 "ch3h00f

FIGURE 4



20970" 215900F

FIGURE 5



205110 245400

FIGURE 6

Dose Response





FIGURE 7



◆ LFN-8

46kd--

30kd-

44bJ--

..kd.

4(2)(b)-.

30kd--

FIGURE 9

CMT.64 Transfectants +/- VSV




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13

CMT 64 Transfectants +/- VSV





FIGURE 14

TAP 1 versus TAP 2 CMT 64 Transfectants +/- VSV



20970" ch9900T

FIGURE 15

CMT 64 Transfectants +/- VSV




FIGURE 16

CTL Response to Influenza




FIGURE 17

CTL Response to Influenza




FIGURE 18

CTL Response to Influenza




FIGURE 19

CTL Response to HSV-1




FIGURE 20

Survival of C57BL/6 and Balb/C Mice Injected with 5×10^5 cells of CMT. 64 or CMT.12.12





FIGURE 21

A



B





FIGURE 22

A



B





FIGURE 23

A



B

	VV-NP	VV-NP + VV-hTAP12
VSV pCTL	1/78,000	1/16,000

FIGURE 24






FIGURE 25



est to shoot

FIGURE 26



203710" chesshot

FIGURE 27




FIGURE 28

A

Murine Splenocytes

Human TAP1 —————

Normal	3×10^4	3×10^5
Control	<u>VV-TAP1,2</u>	

B




FIGURE 29





FIGURE 30

A



B




FIGURE 31





FIGURE 32A




FIGURE 32B




FIGURE 33

TAP1 enhanced the presentation of VSV-NP by B16 cells




FIGURE 34

TAP1 enhanced the presentation of TRP-2 by B16 cells




FIGURE 35




FIGURE 36





FIGURE 37

A



C



B





FIGURE 38

A

Tumor	one month		two months		Ratio ^b	
	CD4% ^a	CD8%	CD4%	CD8%	CD4	CD8
CMT.neo	0.54	0.41				
CMT.1-1	1.02	0.87			1.9	2.1
CMT.1-4			1.07	1.20	2.0	2.9
CMT.1-10	4.19	2.94			7.8	7.2
CMT.2-1	0.24	0.23			0.4	0.6
CMT.2-10	0.12	0.66			0.2	1.6

B




FIGURE 39




FIGURE 40

